WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Options
Query Language
Stem
Sort by:
List Length
1. (WO2013112912) PEPTIDE ANTAGONISTS OF THE CALCITONIN CGRP FAMILY OF PEPTIDE HORMONES AND THEIR USE
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2013/112912 International Application No.: PCT/US2013/023260
Publication Date: 01.08.2013 International Filing Date: 25.01.2013
IPC:
C07K 14/585 (2006.01) ,A61K 38/22 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
14
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435
from animals; from humans
575
Hormones
585
Calcitonins
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
16
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17
from animals; from humans
22
Hormones
Applicants: SOARES, Christopher, J.[US/US]; US
Inventors: SOARES, Christopher, J.; US
Agent: MILLER, Kimberly, J.; Knobbe Martens Olson & Bear LLP 2040 Main Street, Fourteenth Floor Irvine, CA 92614, US
Priority Data:
61/591,23626.01.2012US
Title (EN) PEPTIDE ANTAGONISTS OF THE CALCITONIN CGRP FAMILY OF PEPTIDE HORMONES AND THEIR USE
(FR) ANTAGONISTES PEPTIDIQUES DE LA FAMILLE CALCITONINE CGRP D'HORMONES PEPTIDIQUES ET LEUR UTILISATION
Abstract:
(EN) The embodiments provide a modified calcitonin gene-related peptide antagonist including an N-terminal fragment of modified calcitonin gene-related peptide or related protein family member where at least two residues of the N-terminal fragment are cysteine (Cys) and at least one amino acid comprises a non-threonine substitution of a threonine (Thr) residue; a central core where the central core comprises an oc-helix; and a C-terminal fragment of modified calcitonin gene -related peptide or related protein family member comprising a C-terminal amide and where at least one amino acid of the C-terminal fragment is phenylalanine (Phe), proline (Pro), tyrosine (Tyr) or hydroxyproline (Hyp) or pharmaceutically acceptable salt thereof, as well as compositions, including pharmaceutical compositions, comprising a subject peptide. The embodiments further provide treatment methods, including methods of treating a migraine, the methods generally involving administering to an individual in need thereof an effective amount of a subject peptide or composition.
(FR) Les modes de réalisation de l'invention concernent un antagoniste peptidique modifié associé au gène calcitonine comprenant un fragment N-terminal d'un peptide modifié associé au gène calcitonine ou un membre de la famille protéique associée, au moins deux résidus du fragment N-terminal étant cystéine (Cys) et au moins un acide aminé comprenant une substitution non-thréonine d'un résidu thréonine (Thr) ; un noyau central, le noyau central comprenant une hélice-oc ; et un fragment C-terminal d'un peptide modifié associé à un gène calcitonine ou un membre d'une famille protéique associée comprenant un amide C-terminal et au moins un acide aminé du fragment C-terminal étant phénylalanine (Phe), proline (Pro), tyrosine (Tyr) ou hydroxyproline (Hyp) ou un sel pharmaceutiquement acceptable de ceux-ci, ainsi que des compositions, comprenant des compositions pharmaceutiques, comprenant un peptide de l'invention. Les modes de réalisation concernent en outre des méthodes de traitement, comprenant des méthodes de traitement d'une migraine, les méthodes mettant en jeu en général l'administration à un individu en ayant besoin d'une quantité efficace d'un peptide ou d'une composition de l'invention.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)